Boundless Bio, Inc. (BOLD)
| Previous Close | 3.0100 |
| Open | 3.0700 |
| Bid | 2.9800 x 100 |
| Ask | 3.0500 x 100 |
| Day's Range | 2.9950 - 3.0700 |
| 52 Week Range | 2.8200 - 15.2400 |
| Volume | |
| Avg. Volume | 59,614 |
| Market Cap | 67.569M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.7400 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.33 |
GlobeNewswireBoundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights
Enrollment progressing in BBI-355 POTENTIATE and BBI-825 STARMAP clinical trials, with initial proof-of-concept data expected in the second half of 2025 Cash position of $167 million, with operating runway into the fourth quarter of 2026 SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers
- GlobeNewswire
Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in the 2024 Guggenheim Global Healthcare Conference. A fireside chat session is scheduled for Tuesday, November 12, 2024, in Boston, MA, at 2:3
